Wolf Theiss advises EIC Fund on Series Y shares subscriptions in Captor Therapeutics SPO

Warsaw, 23 March 2026 – Wolf Theiss advised the European Innovation Council Fund (EIC Fund), an investment company financed by the European Commission and headquartered in Luxembourg, on its investment in Series Y newly issued shares of Captor Therapeutics SA, a biopharmaceutical company specialising in targeted protein degradation (TPD) technology.

The EIC Fund is the venture capital investment arm of the European Innovation Council (EIC). With a capitalisation of over EUR4 billion, it bridges the gap between public and private financing, supporting Europe’s most promising startups and scaleups.

Captor Therapeutics is a biopharmaceutical company leveraging TPD technology to discover and develop therapeutics for high unmet medical needs. As part of this SPO, Captor Therapeutics acquired approx. PLN 66 million. The SPO was intermediated by mBank Securities and IPOPEMA Securities. In 2025, Captor Therapeutics was awarded funding under the Horizon Europe EIC Accelerator programme, with the EIC Fund supporting the development of its first‑in‑class MCL‑1 degrader. The proceeds from the new Series Y issuance, together with the earlier grant financing, are intended to support the execution of Phase Ia/Ib clinical studies designed to assess the safety profile and absence of cardiotoxicity in patients with acute myeloid leukaemia.

Wolf Theiss acted as Polish legal counsel to the EIC Fund, assisting with the Series Y subscription process and advising on all Polish law aspects of the investment in Captor Therapeutics.

The Wolf Theiss team was led by Partner Marcin Pietkiewicz, supported by Associate Jan Kaźmierczak (both Corporate M&A).